Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel

Heart

Volumn 101, Issue 15, 2015, Pages 1219-1224

  Widimsky, Petr ^a   Motovska, Zuzana ^a   Bolognese, Leonardo ^b   Dudek, Dariusz ^c   Hamm, Christian ^d   Tanguay, Jean Francois ^e   Berg, Jurrien Ten ^f   Brown, Eileen ^g   LeNarz, LeRoy ^g   Miller, Debra L ^g   Montalescot, Gilles ^h  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Azienda Ospedaliera   (Italy)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g ELI LILLY AND COMPANY   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CORONARY STENTING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMORAL ARTERY; GASTROINTESTINAL HEMORRHAGE; HEMOPERICARDIUM; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; HEMORRHAGE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941564199     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-307686     Document Type: Article

References (30)

1. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
3. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55.
4. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
5. Bellemain-Appaix A, O'Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012;308:2507-16.
6. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
7. Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29:1495-503.
8. Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010;56:550-7.
9. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
10. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.
11. Montalescot G, Bolognese L, Dudek D, et al. A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. Am Heart J 2011;161:650-6.
12. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-65.
13. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47.
14. Amsterdam EA, Peterson ED, Ou FS, et al. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. Am Heart J 2009;158:748-54.
15. Ahmed B, Piper WD, Malenka D, et al. Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv 2009;2:423-9.
16. Ahmed B, Dauerman HL. Women, bleeding, and coronary intervention. Circulation 2013;127:641-9.
17. Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet Published Online First: 16 Mar. 2015.
18. Jolly SS, Mehta SR. Coronary intervention: radial artery access comes of age. Lancet Published Online First:16 Mar. 2015.
19. Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2009;104:507-13.
20. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-9.
21. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16.
22. Amador P, Santos JF, Goncalves S, et al. Comparison of ischemic and bleeding risk scores in non-ST elevation acute coronary syndromes. Acute Card Care 2011;13:68-75.
23. Ariza-Sole A, Sanchez-Salado JC, Lorente V, et al. Is it possible to separate ischemic and bleeding risk in patients with non-ST segment elevation acute coronary syndromes? Int J Cardiol 2014;171:448-50.
24. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
25. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
26. Motovska Z, Widimsky P, Petr R, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. Int J Cardiol 2010;144:255-7.
27. Motovska Z, Widimsky P, Petr R, et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox." J Cardiovasc Pharmacol 2009;53:368-72.
28. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32.
29. Michelson AD, Frelinger AL III, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-63.
30. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403.